(MedPage Today) — SAN FRANCISCO — Dual antiangiogenic therapy for previously treated kidney cancer significantly improved progression-free survival (PFS) versus a single drug, a large randomized trial showed.
Median PFS improved from 10.7…
Source link : https://www.medpagetoday.com/meetingcoverage/ascogu/120094
Author :
Publish date : 2026-02-28 15:00:00
Copyright for syndicated content belongs to the linked Source.













